(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Name | Target PSU Award | |||||||
Jeffrey Nau, Chief Executive Officer | 170,600 | |||||||
Daniel Lochner, Chief Financial Officer | 80,000 | |||||||
John Snisarenko, Chief Commercial Officer | 45,000 |
OYSTER POINT PHARMA, INC. | ||||||||
Date: January 13, 2022 | By: | /s/ Jeffrey Nau | ||||||
Jeffrey Nau, Ph.D., M.M.S. | ||||||||
President, Chief Executive Officer and Director | ||||||||
Cover |
Jan. 13, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Entity Registrant Name | Oyster Point Pharma, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39112 |
Entity Tax Identification Number | 81-1030955 |
Entity Address, Address Line One | 202 Carnegie Center, Suite 109 |
Entity Address, City or Town | Princeton |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 08540 |
City Area Code | (609 |
Local Phone Number | 382-9032 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | OYST |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | true |
Amendment Flag | false |
Entity Central Index Key | 0001720725 |
Document Period End Date | Jan. 09, 2022 |
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end
X-GSN5R-)I_POCARWJ%KGG65, 4NA) %.1H1]46
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M&6'<3^VODJ2NCJ2'O' P;(%1>YH"Y>J02<]5S[7F2MV $O:U^9\3KP6 0%OLM\/!TSJX;M#\
M__JU^.&(_AVY'T;Z0P3UR]C>MHW+PS>+Q:T<35W"1TB+_OG/CR>/3-8W;0?-
M95U47;/="_5FU8]:'=?(!/H[G-_=7,+!LBTVER7<'[MH(!TL^[-)'UC*J.VM
M_G)[XNJ;\].=>$)P%^C.[=B-6E:_!"
M)%P49;P_N\\CNXA55^] N=NPH+O+!